Navigation Links
pWEB::TNC Deletion Cosmid Transposition Kit from EPICENTRE Biotechnologies

ProductspWEB::TNC Deletion Cosmid Transposition Kit from EPICENTRE Biotechnologies
Company EPICENTRE Biotechnologies
Item pWEB::TNC Deletion Cosmid Transposition Kit
Price $350.00
Description The pWEB::TNC™ Deletion Cosmid Cloning Kit enables you to prepare, in about two days, a complete and unbiased primary cosmid library of genomic DNA for subsequent use in making nested deletion sublibraries. High efficiency cosmid library construction is accomplished using easy and highly reproducible kit protocols. First, genomic DNA is randomly sheared by passing it through a syringe needle. Next, the sheared DNA is end-repaired using reagents in the kit, and then size selected on a gel by comparison with a supplied 40-kb standard. Finally, the size-selected DNA is ligated into the supplied linearized and dephosphorylated pWEB::TNC Cosmid Vector, packaged using ultra-high efficiency MaxPlax™ Lambda Packaging Extracts (>109 pfu/mg for phage lambda), also in the kit, and plated on the supplied EPBOS™ plating cells.
Info EPICENTRE BiotechnologiesEPICENTRE Biotechnologies
726 Post Road
Madison, WI 53713
USA
Customer Service: 800-284-8474
Tech Support: 800-284-8474
Fax Number: 608-442-6114
Web Site: http://www.epibio.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. * Quick & Easy E. coli Gene Deletion Kit from Gene Bridges GmbH
2. EZ-Tn5 Plasmid-Based Deletion Machine from EPICENTRE Biotechnologies
3. Yeast Deletion Parental Strains S. cerevisiae Hansen BY4741 from Invitrogen
4. Yeast Deletion Parental Strains S. cerevisiae Hansen BY4742 from Invitrogen
5. Kilo Sequencing Deletion Kit from Takara Mirus Bio
6. pWEB Cosmid Cloning Kit from EPICENTRE Biotechnologies
7. GELase LMP Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
8. GELase LMP Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
9. Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies
10. Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies
11. GELase LMT Agarose Gel-Digesting Preparation from EPICENTRE Biotechnologies
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Annexin V Binding Buffer from BD Biosciences Pharmingen
Mouse Anti-Cytokeratin 8 + 18 + 19 Monoclonal Antibody, Unconjugated, Clone 2A4 from Abcam
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Biology Products:
(Date:11/4/2009).... Louis, MO, November 4, 2009 Childhood obesity i...ns. With more than one fourth of advertising on da...nd beverages and continuing questions about the ro...ember/December issue of the Journal of Nutrition ...ing aimed at children might be a large contributor...
(Date:11/4/2009)..., PORTOLA VALLEY, Calif., Oct. 19 ...olecular sensing and imaging devices which shed li...that it has signed exclusive distribution deals fo...nsors. The markets covered include Australia, New...enelux), Suriname, Italy, France, Spain, Portugal,...
(Date:11/4/2009)..., RIDGE, N.Y., Oct. 21 What,s the ...eventing accidental death resulting from prescript...s with good intentions, however, may be unaware th...ting their teens from the ticking timebomb of pres...leader in premium-quality medical supplies, has fo...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3AMA Medicare Campaign Kicks Off With New TV Ads 59585 1AMA Medicare Campaign Kicks Off With New TV Ads 59585 2AMA Medicare Campaign Kicks Off With New TV Ads 59585 3Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2
...of Standards and Technology (NIST) last week issue... and growing field of tissue engineering for medic...al tissue scaffold material that have been measure...es of porosity. , Three-dimensional tissue scaffo...adable materials that are meant to be implanted in...
...nt pieces of the climate change puzzle together is...is a key piece of this puzzle, but the size and sh...opardises the reliability of all current predictio...ct has been launched at the University of Leeds to...te. , Aerosols are small particles suspended in...
...f melanin -- the color pigment in skin and hair --...sed susceptibility to nicotine dependence and toba...rs, according to scientists., "We have found that...to the number of cigarettes smoked daily, levels o... African Americans," said Gary King, professor of ...
Other Biology News:NIST issues first reference material for tissue engineering 2Aerosol: A key piece of the climate change puzzle 2Skin color clue to nicotine dependence 2
(Date:11/5/2009)...FREMONT, Calif., Nov. 5 ...S), a leading developer of state-of-the-art geneti...er Sears, Ph.D. has joined the company,s Scientifi...designing and commercializing novel molecular diag...s, and on the development of computational biology...
(Date:11/5/2009)... LASIK Surgery and vision corre... directory were actively involved at the recently ...2009 Annual Meeting in San Francisco, California. ...MD, Dr. Jonathan Davidorf, MD, Dr. Peter Rapoza, M..., Dr. R. Wayne Bowman, MD, Dr. Edward Manche, MD, ...
(Date:11/4/2009)...HUNTSVILLE, Ala., Nov. 4 DIATHERIX...om ), today presented at the Michigan Security Ne...ce in Dearborn, Mich. Dennis Grimaud, Chairman and...he impact of the company,s advanced molecular diag...nse, infectious disease diagnosis and military eff...
(Date:11/4/2009)...SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ ...rted its financial results for the third quarter e...uarter ended September 30, 2009 improved to $31.0 ...oss of $37.0 million or $0.40 per share in the thi...ake improvements to its operating efficiencies as ...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10